(taurolidine and heparin) catheter lock solution

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

11mo

CRMDPhase 3$576M

(taurolidine and heparin) catheter lock solution Phase 3 Results Expected

(taurolidine and heparin) catheter lock solution• Central Line Associated Blood Stream Infections (CLABSI)200

Jan 15Estimated

00%

Competitive Landscape

0 competitors in Central Line Associated Blood Stream Infections (CLABSI)

Drug Information

Target Indication

Central Line Associated Blood Stream Infections (CLABSI)

Clinical Trial

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

CRMD

CorMedix Inc.

Related Pipeline

Kidney Failure, Chronic

Contrast-Induced Acute Kidney Injury